Galapagos and Merck & Co expand deal
This article was originally published in Scrip
Executive Summary
Galapagos and Merck & Co have expanded an agreement that covered obesity and diabetes drug candidates to include small-molecule drug candidates for preclinical development in atherosclerosis.